Fortrea and Emery Pharma Collaborate on Drug-Drug Interaction Studies
DURHAM, N.C. — Fortrea (Nasdaq: FTRE), a prominent contract research organization (CRO), has launched a strategic collaboration with Emery Pharma, another key player in the analytical and bioanalytical CRO field. This partnership aims to enhance the rapid testing of rifampin, a drug central to assessing drug-drug interactions (DDI), according to stringent FDA guidelines.
Enhancing Drug-Drug Interaction Studies
Fortrea has chosen to collaborate with Emery Pharma due to its robust expertise in analytical testing, which plays a vital role in supporting Fortrea's global clinical programs. Emery Pharma specializes in conducting precise tests to ensure that impurities in rifampin are maintained at levels below the Acceptable Intake (AI) Limit set by regulatory bodies like the FDA. The focus on rifampin, known to induce the CYP3A4 isoenzyme, is especially significant as it is frequently cited as the preferred agent for conducting DDI evaluations.
Commitment to Safety and Efficiency
Oren Cohen, M.D., chief medical officer and president of Clinical Pharmacology Services at Fortrea, emphasized the importance of this collaboration in enhancing participant safety and streamlining study designs. "By leveraging the capabilities of Emery Pharma, we are enabling sponsors to conduct earlier phase trials more efficiently, reduce risks, and improve the overall quality of data,” he stated. The partnership promises innovative study designs that adhere to the highest standards of compliance and safety.
Implications for Drug Development
Drug-drug interaction studies are critical for the development of new therapeutics, and rifampin has been a staple in this area until recent concerns regarding its safety due to nitrosamine impurities emerged. Following an FDA review that revealed substantial levels of 1-methyl-4-nitrosopiperazine (MNP) in rifampin, pharmaceutical researchers were urged to reconsider its use. While alternatives emerged, they often come with their own safety issues and longer activation periods.
Regulatory Updates and Testing Innovations
In recent developments, the FDA has acknowledged these challenges and raised the acceptable MNP impurity limits, reopening discussions on the viability of rifampin in pharmacological studies. This crucial shift advances Fortrea's broader clinical pharmacology trials, marking a significant step towards compliant testing methodologies that maintain high safety standards.
About Fortrea
Fortrea is a leading global provider dedicated to clinical development solutions across the life sciences spectrum. Partnering with a wide range of biopharmaceutical, biotechnology, and medical device firms, Fortrea aims to facilitate the transition of innovative healthcare products to market. With over three decades of expertise spanning more than 20 therapeutic areas, Fortrea prides itself on its commitment to scientific excellence and comprehensive clinical trial management.
About Emery Pharma
Located in Alameda, California, Emery Pharma is recognized for its profound scientific leadership and expertise in impurity analysis tailored to meet regulatory standards. They specialize in supporting various stages of drug development from early discovery to clinical trials. Their sophisticated testing platforms, including liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry, allow for highly precise analysis, essential in navigating the complexities of modern drug testing.
In conclusion, the collaboration between Fortrea and Emery Pharma is set to transform approaches to clinical trials and drug development, ensuring the delivery of safer, more effective therapies in line with evolving regulatory standards.
Frequently Asked Questions
What is the significance of the collaboration between Fortrea and Emery Pharma?
This partnership is crucial for advancing drug-drug interaction studies while maintaining FDA compliance, ensuring participant safety and data integrity.
How does rifampin play a role in drug-drug interaction studies?
Rifampin is widely used for its ability to induce the CYP3A4 isoenzyme, making it a preferred choice in assessing the interactions between different drugs.
What are the safety concerns associated with rifampin?
Recent evaluations have raised issues regarding the presence of nitrosamine impurities in rifampin, prompting regulatory changes and evaluations of acceptable limits.
What does Fortrea bring to the partnership?
Fortrea offers extensive expertise in clinical trial management and regulatory compliance, ensuring that studies conducted through this collaboration are efficient and meet high safety standards.
How can researchers benefit from the testing innovations introduced by this partnership?
Researchers can access innovative and compliant testing methodologies tailored for early-phase trials, helping to expedite timelines and enhance data quality.
